First FDA authorization for next-generation sequencer.
作者信息
Collins Francis S, Hamburg Margaret A
机构信息
From the Office of the Director, National Institutes of Health, Bethesda, MD (F.S.C.); and the Office of the Commissioner, Food and Drug Administration, Department of Health and Human Services, Silver Spring, MD (M.A.H.).
出版信息
N Engl J Med. 2013 Dec 19;369(25):2369-71. doi: 10.1056/NEJMp1314561. Epub 2013 Nov 19.
Abstract
摘要
相似文献
1
First FDA authorization for next-generation sequencer.美国食品药品监督管理局首次批准下一代测序仪。
N Engl J Med. 2013 Dec 19;369(25):2369-71. doi: 10.1056/NEJMp1314561. Epub 2013 Nov 19.
2
Regulations, economics hindering adoption of personalized medicine.法规和经济因素阻碍个性化医疗的采用。
Am J Health Syst Pharm. 2011 Mar 1;68(5):372-4. doi: 10.2146/news110012.
3
4
DNA sequencers: the next generation.DNA测序仪：下一代产品。
Anal Chem. 2009 Mar 1;81(5):1736-40. doi: 10.1021/ac802712u.
5
FDA notifications. FC2 female condom receives FDA approval.美国食品药品监督管理局通知。FC2女用避孕套获得美国食品药品监督管理局批准。
AIDS Alert. 2009 May;24(5):58-9.
6
Technology: Read the instructions.技术：阅读说明书。
Nature. 2016 Sep 8;537(7619):S54-6. doi: 10.1038/537S54a.
7
Industry perspective on FDA regulation of medical devices and the practice of medicine.行业对美国食品药品监督管理局（FDA）医疗器械监管及医疗实践的看法。
Ann Thorac Surg. 1996 Jan;61(1):485-6; discussion 493-8. doi: 10.1016/0003-4975(95)00989-2.
8
Will new FDA rules hasten device approval?美国食品药品监督管理局的新规定会加快器械审批吗？
Hosp Mater Manage. 2003 Jul;28(7):2, 16.
9
FDA unveils 25 initial 510(k) changes, refers controversial recommendations to the Institute of Medicine (IOM).美国食品药品监督管理局公布了25项初步的510(k)变更，并将有争议的建议提交给医学研究所（IOM）。
Health Care Law Mon. 2011 Jun;2011(6):2-7.
10
Clarification: 510k is premarket notification; it provides no patent or FDA approval.说明：510k是上市前通知；它不提供专利或FDA批准。
J Drugs Dermatol. 2008 Feb;7(2):105.
引用本文的文献
1
Precision Medicine for Cancer and Health Equity in Latin America: Generating Understanding for Policy and Health System Shaping.拉丁美洲癌症精准医学与健康公平：增进对政策制定和卫生系统塑造的理解
Int J Environ Res Public Health. 2025 Aug 5;22(8):1220. doi: 10.3390/ijerph22081220.
2
Review on Advancement of AI in Cell Engineering and Molecular Biology.人工智能在细胞工程和分子生物学中的进展综述
Methods Mol Biol. 2025;2952:169-192. doi: 10.1007/978-1-0716-4690-8_10.
3
Oncogenic gene fusions in cancer: from biology to therapy.癌症中的致癌基因融合：从生物学至治疗
Signal Transduct Target Ther. 2025 Apr 14;10(1):111. doi: 10.1038/s41392-025-02161-7.
4
Artificial intelligence (AI) in personalized medicine: AI-generated personalized therapy regimens based on genetic and medical history: short communication.个性化医疗中的人工智能：基于遗传和病史的人工智能生成的个性化治疗方案：简短通讯
Ann Med Surg (Lond). 2023 Sep 13;85(11):5831-5833. doi: 10.1097/MS9.0000000000001320. eCollection 2023 Nov.
5
RESCUE: a validated Nanopore pipeline to classify bacteria through long-read, 16S-ITS-23S rRNA sequencing.RESCUE：一种经过验证的纳米孔流程，通过长读长16S-ITS-23S rRNA测序对细菌进行分类。
Front Microbiol. 2023 Jul 20;14:1201064. doi: 10.3389/fmicb.2023.1201064. eCollection 2023.
6
Network analysis for estimating standardization trends in genomics using MEDLINE.基于 MEDLINE 的基因组学标准化趋势估计的网络分析。
BMC Med Res Methodol. 2022 Oct 7;22(1):263. doi: 10.1186/s12874-022-01740-4.
7
FDA-led consortium studies advance quality control of targeted next generation sequencing assays for precision oncology.由美国食品药品监督管理局牵头的联盟开展研究，推进用于精准肿瘤学的靶向新一代测序检测的质量控制。
Precis Cancer Med. 2021 Dec;4. doi: 10.21037/pcm-21-29. Epub 2021 Dec 30.
8
Comparison of Illumina and Oxford Nanopore Sequencing Technologies for Pathogen Detection from Clinical Matrices Using Molecular Inversion Probes.Illumina 和 Oxford Nanopore 测序技术在基于分子反转探针的临床样本病原体检测中的比较。
J Mol Diagn. 2022 Apr;24(4):395-405. doi: 10.1016/j.jmoldx.2021.12.005. Epub 2022 Jan 25.
9
Retrospective clinical trial experimentally validates glioblastoma genome-wide pattern of DNA copy-number alterations predictor of survival.回顾性临床试验通过实验验证了胶质母细胞瘤全基因组DNA拷贝数改变模式可作为生存预测指标。
APL Bioeng. 2020 May 15;4(2):026106. doi: 10.1063/1.5142559. eCollection 2020 Jun.
10
Application of genome analysis strategies in the clinical testing for pediatric diseases.基因组分析策略在儿科疾病临床检测中的应用。
Pediatr Investig. 2018 Jul 16;2(2):72-81. doi: 10.1002/ped4.12044.
本文引用的文献
1
Do pharmacogenetics have a role in the dosing of vitamin K antagonists?药物遗传学在维生素K拮抗剂的剂量确定中是否起作用？
N Engl J Med. 2013 Dec 12;369(24):2345-6. doi: 10.1056/NEJMe1313682. Epub 2013 Nov 19.
2
Mutational landscape and significance across 12 major cancer types.12 种主要癌症类型的突变特征及意义。
Nature. 2013 Oct 17;502(7471):333-339. doi: 10.1038/nature12634.
3
Genomics, health care, and society.基因组学、医疗保健与社会。
N Engl J Med. 2011 Sep 15;365(11):1033-41. doi: 10.1056/NEJMra1010517.
Zotero 插件